Reduced protective efficacy of a blood-stage malaria vaccine by concurrent nematode infection.
Helminth infections, which are prevalent in areas where malaria is endemic, have been shown to modulate immune responses to unrelated pathogens and have been implicated in poor efficacy of malaria vaccines in humans. We established a murine coinfection model involving blood-stage Plasmodium chabaudi AS malaria and a gastrointestinal nematode, Heligmosomoides polygyrus, to investigate the impact of nematode infection on the protective efficacy of a malaria vaccine. C57BL/6 mice immunized with crude blood-stage P. chabaudi AS antigen in TiterMax adjuvant developed strong protection against malaria challenge. The same immunization protocol failed to induce strong protection in H. polygyrus-infected mice. Immunized nematode-infected mice produced significantly lower levels of malaria-specific antibody than nematode-free mice produced. In response to nematode and malarial antigens, spleen cells from immunized nematode-infected mice produced significantly lower levels of gamma interferon but more interleukin-4 (IL-4), IL-13, and IL-10 in vitro than spleen cells from immunized nematode-free mice produced. Furthermore, H. polygyrus infection also induced a strong transforming growth factor beta1 response in vivo and in vitro. Deworming treatment of H. polygyrus-infected mice before antimalarial immunization, but not deworming treatment after antimalarial immunization, restored the protective immunity to malaria challenge. These results demonstrate that concurrent nematode infection strongly modulates immune responses induced by an experimental malaria vaccine and consequently suppresses the protective efficacy of the vaccine against malaria challenge.
Research Institute of McGill University Health Centre, Room L11-409, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada. zhong.su@mail.mcgill.ca
Zhong
Z
Su
Mariela
M
Segura
Mary M
MM
Stevenson
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage; D016207:Cytokines / Q000096:biosynthesis / Q000378:metabolism; D005260:Female; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008288:Malaria / Q000276:immunology / Q000469:parasitology* / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009351:Nematospiroides dubius / Q000276:immunology; D016788:Plasmodium chabaudi / Q000254:growth & development / Q000276:immunology; D017206:Strongylida Infections / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism
D000276:Adjuvants, Immunologic; D000871:Anthelmintics; D016207:Cytokines; D017780:Malaria Vaccines